Opinion|Videos|February 21, 2025
Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice
Panelists discuss the types of questions that real-world (RW) data can answer in comparison to with clinical trial data, and how it they can complement clinical findings in treatment decision-making.
Advertisement
Episodes in this series
Video content above is prompted by the following:
In comparison with clinical data, what questions can RW data answer?
Advertisement
Related to this article
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.
Premal H. Thaker, MD, MS, discusses INCB123667 in ovarian cancer and the ongoing MAESTRA 2 study.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
The FDA set a PDUFA target action date of April 28, 2027, for varegacestat in desmoid tumors.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
2
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer
5